Ross Aarons

Ross Aarons is a seasoned professional in corporate development and business strategy, currently serving as Sr. Director of Corporate Development at Jazz Pharmaceuticals since July 2022. Notable achievements include securing a license agreement with Zymeworks for zanidatamab, acquiring Redx's KRAS inhibitor program, and the acquisition of Chimerix. Prior experience includes roles at AbbVie as Associate Director of Business Development & Acquisitions, where responsibilities encompassed negotiations and collaborations to further business goals, and at Arysta LifeScience as Global M&A Manager, overseeing various corporate development activities. Earlier roles include Global M&A Associate at TAP Advisors and Investment Banking Analyst at PwC. Ross holds an MBA from Northwestern University's Kellogg School of Management and a B.S. in Finance and Economics from Penn State University.